Phase 2 Study of AI-Designed Personalised Neoantigen Cancer Vaccine, EVX-01, in Combination With Pembrolizumab in Advanced Melanoma
Time: 9:30 am
day: Day One
Details:
- Discussing AI designed personalised peptide vaccines
- Understanding the phase 2 clinical testing
- Considering antigen specific T-cell responses and Biomarker analysis
